25
6
6
↑25
↓6
—6
Evidence suggests Melatonin mayincreaseMitochondrial health.
46 studies (37 claims)
Moderate consensus
Typical effective dose 3 (2.5–6) mgacross 13 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| melatonin administered systemically or topically | Decreases - ameliorate | oral health conditions or dental procedures | Human | patients involved with oral health conditions or dental procedures | Not specified | Melatonin as an adjunctive treatment on dental procedures: A systematic review.cited 3× |
| oral melatonin supplementation | Increases - effective | hair health | Human | — | 0.0033% or 0.1% topical solution once daily; 1.5 mg oral melatonin twice daily. | Melatonin and the Human Hair Follicle.cited 9× |
| topical melatonin | Increases - effective | hair health | Human | — | 0.0033% or 0.1% topical solution once daily; 1.5 mg oral melatonin twice daily. | Melatonin and the Human Hair Follicle.cited 9× |
| topical melatonin use | Increases - observed positive outcomes | hair health | Human | subjects with androgenetic alopecia (AGA) | 0.0033% or 0.1% topical solution once daily; 1.5 mg oral melatonin twice daily. | Melatonin and the Human Hair Follicle.cited 9× |
| melatonin prolonged release (PR) 2 mg 1-2 h before bedtime | Increases - was associated with significant improvements relative to placebo in | many sleep and daytime parameters, including sleep quality and latency, morning alertness and health-related quality of life | Human | patients with primary insomnia aged ≥55 years | 2 mg, 1-2 hours before bedtime. | Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.cited 35× |
| melatonin (MLT) | No effect - associated with | a wide variety of health outcomes | Human | clinically and methodologically heterogeneous populations | Not specified | Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action.cited 55× |
| melatonin (MLT) | No effect - effects on health | health-related outcome measure | Human | clinically and methodologically heterogeneous populations | Not specified | Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action.cited 55× |
| melatonin | No effect - review the evidence on the effect | cardiovascular health | Human | — | Not specified | The Role of the Circadian Rhythm in Dyslipidaemia and Vascular Inflammation Leading to Atherosclerosis.cited 13× |
| Melatonin | No effect - supports | gastrointestinal health | Human | — | Not specified | Bioactive Peptides in Dairy Milk: Highlighting the Role of Melatonin.cited 1× |
| melatonin | Decreases - may reduce | health care exhaustion | Human | — | Not specified | Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.cited 29× |
| melatonin | No effect - unlikely to be beneficial | health in NCDs | Human | — | Suggested effective cytoprotective dose: 100 mg/day; current clinical trial doses: 2-10 mg. | Melatonin as a Chronobiotic and Cytoprotector in Non-communicable Diseases: More than an Antioxidant.cited 3× |
| melatonin | No effect - would allow the clinician/research to proper interpret its role in health maintenance | health maintenance | Human | — | Not specified | New insights into the function of melatonin and its role in metabolic disturbances.cited 39× |
| melatonin | No effect - participates in the health management of bone and cartilage | health management of bone and cartilage | Human | — | Not specified | Insight into the roles of melatonin in bone tissue and bone‑related diseases (Review).cited 43× |
| melatonin | No effect - no significant effect | health-related quality of life | Human | youth (ages 8-18 years) with PPCS at 4 to 6 weeks after mild traumatic brain injury | 3 mg or 10 mg melatonin (frequency not specified). | Efficacy of Melatonin in Children With Postconcussive Symptoms: A Randomized Clinical Trial.cited 30× |
| melatonin | Increases - more improvement was also seen | Health-related quality of life (QOL) | Human | type 2 diabetic patients suffering from painful diabetic neuropathy (PDN) | 3 mg/day for 1 week, then 6 mg/day for 7 weeks. | Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial.cited 13× |
| melatonin | No effect - implicated in | human health aspects | Human | human | — | Melatonin: an internal signal for daily and seasonal timing. |
| melatonin | Increases - can affect | intervertebral disc (IVD) health | Human | — | Not specified | Melatonin: Evolving Physiological Understanding and Potential Therapeutic Role in Pain Medicine Including Intervertebral Disc Degeneration.cited 1× |
| melatonin | Increases - improved | mental health | Human | individuals experiencing co-occurring disorders of mood and sleep disturbance post-injury | — | The Utility of Melatonin for the Treatment of Sleep Disturbance After Traumatic Brain Injury: A Scoping Review.cited 8× |
| melatonin | No effect - influences | oral health | HumanAnimal | — | — | Subcellular distribution of melatonin receptors in human parotid glands. |
| melatonin | Increases - improving | overall health | Human | afflicted patients | Not specified | Therapeutic Benefits of Melatonin against COVID-19.cited 4× |
| melatonin (5 mg) | No effect - no statistically significant between-group differences | Personal Health Questionnaire Depression Scale (PHQ-8) | Human | males 18 years of age and older in recovery from substance use | 5 mg melatonin daily. | The Effect of Melatonin Upon Postacute Withdrawal Among Males in a Residential Treatment Program (M-PAWS): A Randomized, Double-blind, Placebo-controlled Trial.cited 3× |
| melatonin | Decreases - lowering | risk of nicotine‑related health issues | Human | — | Not specified | Exploring the association between melatonin and nicotine dependence (Review).cited 1× |
| paediatric prolonged-release melatonin (PedPRM) | No effect - will examine the efficacy | overall mental health | Human | children and adolescents with PTSD | Not specified in the abstract. | Protocol MelatoSom-Kids-PTSD: sleep disturbances in children and adolescents with post-traumatic stress disorder (PTSD) - a randomized double-blind placebo-controlled trial to investigate the efficacy of paediatric prolonged-release melatonin. |
| lemon juice after melatonin treatment | No effect - had no adverse effects | animals' health | HumanAnimal | mice | 1 mL, 1.5 mL, 2 mL (drink assay); 4 mL (diet assay). | The Effect of Lemon Juice (Citrus limon L.) Treated with Melatonin on the Health Status and Treatment of K14HPV16 Mice.cited 1× |
| melatonin treatment | Increases - had positive effects | children's health | Human | children with delayed Dim Light Melatonin Onset | Not specified (treatment involved full dose for 3 weeks, half dose for 1 week, then discontinuation). | Termination of short term melatonin treatment in children with delayed Dim Light Melatonin Onset: effects on sleep, health, behavior problems, and parenting stress.cited 15× |
| melatonin treatment | Decreases - deteriorated | health | Human | children with delayed Dim Light Melatonin Onset | Not specified (treatment involved full dose for 3 weeks, half dose for 1 week, then discontinuation). | Termination of short term melatonin treatment in children with delayed Dim Light Melatonin Onset: effects on sleep, health, behavior problems, and parenting stress.cited 15× |
| melatonin treatment | No effect - can be sustained over a long period of time without substantial deviation | development of children with respect to sleep quality, puberty development and mental health scores | Human | children | Mean dose 2.69 mg (range 0.3–10 mg). | Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia.cited 50× |
| standard of care plus melatonin at a dose of 3 mg three times daily for 14 d | Decreases - significantly shorter | mean time of hospital discharge of patients and return to baseline health | Human | hospitalized patients with confirmed mild to moderate COVID-19 | 3 mg three times daily | Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.cited 58× |
| melatonin supplementation | Decreases - may prevent the adverse health consequences | adverse health consequences of obesity | Human | — | 6 mg daily. | A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women.cited 69× |
| melatonin supplementation | Increases - increased | mental health on the SF-36 v1 questionnaire | Human | patients with traumatic brain injury (TBI) | 2 mg prolonged-release melatonin (Circadin®) nightly, 2 hours before bedtime. | Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial.cited 88× |
| melatonin supplementation | Increases - improves | reproductive health compromised by lactational BPS exposure | Animal | male offspring (mice) | 3 mg/kg body weight | Melatonin Improves Lactational Bisphenol S Induced Pre-Pubertal and Pubertal Testicular Impairments in Offspring. |
| balanced melatonin timing | Increases - improve | circadian health | Human | patients with glaucoma | Not specified | Circadian Disruption in Glaucoma: Causes, Consequences, and Countermeasures.cited 2× |
| exercise and/or melatonin | Increases - restoring | muscle health | Animal | Bmal1-deficient mice | Not specified | Melatonin and Exercise Restore Myogenesis and Mitochondrial Dynamics Deficits Associated With Sarcopenia in iMS-Bmal1-/- Mice. |
| melatonin present in edible plants | Increases - may improve | human health | Human | human | Not specified | Melatonin in traditional Mediterranean diets.cited 82× |
| large intake of plant foodstuffs rich in bioactive phytochemicals, such as melatonin | No effect - attributed to | health-promoting effects | Human | — | Not specified | Melatonin in traditional Mediterranean diets.cited 82× |
| Treatment with melatonin | Increases - might result in | a wide range of health benefits, including improved quality of life and reduced healthcare costs | Human | — | Not specified | Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period.cited 53× |
| microbial production of melatonin | Increases - improve | human health | Human | human | Not specified | Microbial production of beneficial indoleamines (serotonin and melatonin) with potential application to biotechnological products for human health.cited 13× |
| melatonin-producing microbes | Increases - positive effects | human health | Human | human | Not specified | Microbial production of beneficial indoleamines (serotonin and melatonin) with potential application to biotechnological products for human health.cited 13× |
| 3 mg melatonin | No effect - difference between groups | referrals to mental health services during admission | Human | adult participants, aged 50 and older, undergoing elective or semi-elective cardiac surgery | 3 mg melatonin administered daily. | The Healthy Heart-Mind trial: melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled trial.cited 10× |
| endogenous melatonin | Increases - importance in cardiovascular health | cardiovascular health | Human | — | Not specified. | Melatonin attenuates chemical-induced cardiotoxicity.cited 6× |
| natural compound, composed of melatonin (1,5 mg) and cannabis extracts (2.5 mg CBD) | Increases - evidenced | good general health perceptions | Human | patients with sleep disorders | 1.5 mg melatonin and 2.5 mg CBD (20 drops sublingually overnight). | Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts.cited 3× |
| melatonin treatment during the late fetal and early neonatal period | Increases - might result in a wide range of health benefits, improved quality of life, and may help limit complications | health benefits, quality of life, complications | Human | late fetal and early neonatal period | Not specified | Potential Utility of Melatonin in Preeclampsia, Intrauterine Fetal Growth Retardation, and Perinatal Asphyxia.cited 48× |
| Food supplements containing soy isoflavones, 8-PN, and melatonin | Increases - improving | health-related quality of life across all domains | Human | postmenopausal women | 54.4 mg standardized soy isoflavones (including 24.5 mg genistein and 16.3 mg daidzein), 100 µg 8-PN, and 1 mg melatonin once daily. | Combination of Soy Isoflavones, 8-Prenylnaringenin and Melatonin Improves Hot Flashes and Health-Related Quality of Life Outcomes in Postmenopausal Women: Flavie Study. |
| Topical administration of melatonin | Increases - has a positive effect on | periodontal health and osseointegration | Human | — | Not specified | Therapeutic potential of melatonin in oral medicine and periodontology.cited 30× |